Alaunos Therapeutics

Update in progress

TCRT (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Alaunos Therapeutics, Inc. is a clinical-stage company focused on oncology cell therapies. It also develops small-molecule programs for obesity and other metabolic disorders, including an oral obesity compound aimed at improving on injectable GLP-1 therapies by preserving lean muscle mass. The company evaluates ALN1001 and related derivatives for lipid deposition and gene expression, and operates the hunTR TCR discovery platform to target driver mutations. Founded in 2003, based in Houston, Texas.

Company score

Sentiment: -0.19; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.13; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.14; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.13; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive